MOR.DE

MorphoSys AG [MOR.DE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MOR.DE Stock Summary

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

Has a high level of debt. Debt-to-Equity ratio of 12.97 is considered high.

Earnings are expected to fall -100% next year

MOR.DE has less than 1 year of cash runway

Top 10 Correlated ETFs

MOR.DE

Top 10 Correlated Stocks

MOR.DE

In the News

MOR.DE Financial details

Company Rating

Strong Buy

Market Cap

2.56B

Income

-189.19M

Revenue

238.36M

Book val./share

1.3

Cash/share

18.16

Dividend

Dividend %

Employees

524

Optionable

Shortable

Yes

Earnings

29 Apr 2024

P/E

12.49

Forward P/E

PEG

4.45

P/S

5.07

P/B

36.28

P/C

3.73

P/FCF

-6.69

Quick Ratio

3.14

Current Ratio

3.57

Debt / Equity

12.97

LT Debt / Equity

12.68

EPS (TTM)

-5.66

EPS next Y

EPS next Q

EPS this Y

25.11%

EPS next Y

EPS next 5Y

EPS last 5Y

11.15%

Revenue last 5Y

27.13%

Revenue Q/Q

-7.4%

EPS Q/Q

-136.57%

SMA20

1.52%

SMA50

48.89%

SMA100

204.55%

Inst Own

0.32%

Inst Trans

0.83%

ROA

ROE

96%

ROC

-0.11%

Gross Margin

77%

Oper. Margin

-81%

Profit Margin

35%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

14.52-68.0

52W High

-0.44%

52W Low

+383.57%

RSI

Rel Volume

0.26

Avg Volume

474.92K

Volume

122.12K

Perf Week

1.27%

Perf Month

3.36%

Perf Quarter

147.99%

Perf Half Y

168.76%

Beta

0.603

Volatility

0.3%, 0.78%

Prev Close

0.15%

Price

67.7

Change

-0.22%

MOR.DE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.27	10.08	5.38	8.15	6.94
Net income per share	-3.26	3.01	-15.4	-4.42	-5.53
Operating cash flow per share	-2.54	1.08	-14.41	-10.74	-8.62
Free cash flow per share	-2.65	-0.43	-15.2	-11.18	-8.71
Cash per share	8.62	33.52	29.75	26.56	19.9
Book value per share	12.49	19.1	7.33	4.61	1.43
Tangible book value per share	11.07	16.92	-27.81	-31.78	-33.15
Share holders equity per share	12.49	19.1	7.33	4.61	1.43
Interest debt per share	1.42	12.74	15.19	13.35	21.74
Market cap	4.01B	3.05B	1.11B	451.54M	1.17B
Enterprise value	4.01B	3.26B	1.31B	388.65M	1.65B
P/E ratio	-38.97	31.17	-2.16	-2.99	-6.18
Price to sales ratio	55.95	9.31	6.19	1.62	4.92
POCF ratio	-50.1	86.5	-2.31	-1.23	-3.96
PFCF ratio	-47.9	-216.89	-2.19	-1.18	-3.93
P/B Ratio	10.17	4.91	4.54	2.87	23.91
PTB ratio	10.17	4.91	4.54	2.87	23.91
EV to sales	55.92	9.95	7.32	1.4	6.93
Enterprise value over EBITDA	-40.59	25.52	-7.34	2.25	-16.88
EV to operating cash flow	-50.07	92.41	-2.73	-1.06	-5.58
EV to free cash flow	-47.88	-231.7	-2.59	-1.02	-5.52
Earnings yield	-0.03	0.03	-0.46	-0.33	-0.16
Free cash flow yield	-0.02	0	-0.46	-0.85	-0.25
Debt to equity	0.11	0.51	1.33	2.16	12.97
Debt to assets	0.09	0.19	0.13	0.14	0.31
Net debt to EBITDA	0.02	1.63	-1.13	-0.36	-4.88
Current ratio	4.93	6.02	3.98	3.91	3.08
Interest coverage	-46.26	1.24	-1.53	1.39	-2.3
Income quality	0.78	0.36	0.94	2.43	1.56
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.51	0.16	0.44	0.3	0.36
Research and developement to revenue	1.51	0.43	1.25	1.07	1.19
Intangibles to total assets	0.09	0.04	0.46	0.52	0.59
Capex to operating cash flow	0.05	-1.4	0.05	0.04	0.01
Capex to revenue	-0.05	-0.15	-0.15	-0.05	-0.01
Capex to depreciation	-0.59	-5.92	-2.59	-1.45	-0.27
Stock based compensation to revenue	0.09	0.03	0.01	0.01	0.11
Graham number	30.26	35.97	50.41	21.41	13.34
ROIC	-0.21	0.53	-0.39	-2.58	-0.36
Return on tangible assets	-0.23	0.06	-0.37	-0.13	-0.23
Graham Net	5.89	3.83	-37.21	-36.19	-35.89
Working capital	242.13M	1.01B	848.43M	810.69M	549.71M
Tangible asset value	349.9M	550.33M	-929.02M	-1.09B	-1.14B
Net current asset value	201.96M	168.63M	-1.18B	-1.15B	-1.16B
Invested capital	0.11	0.51	1.33	2.16	12.97
Average receivables	19.19M	55.09M	87.81M	99.07M	77.5M
Average payables	8.94M	29.11M	60.67M	56.18M	33.48M
Average inventory	266.69K	5.13M	15.36M	22.5M	43.16M
Days sales outstanding	103.47	100.06	174.35	147.37	65.34
Days payables outstanding	321.8	1.89K	836.41	289.62	177.56
Days of inventory on hand	8.7	396.37	235.27	182.07	388.22
Receivables turnover	3.53	3.65	2.09	2.48	5.59
Payables turnover	1.13	0.19	0.44	1.26	2.06
Inventory turnover	41.93	0.92	1.55	2	0.94
ROE	-0.26	0.16	-2.1	-0.96	-3.87
Capex per share	-0.12	-1.52	-0.78	-0.45	-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.39	1.82	1.56	1.87	1.57
Net income per share	9.64	-1.28	-2.16	-3.5	1.28
Operating cash flow per share	-3.08	-2.08	-3.69	-0.99	-1.5
Free cash flow per share	-3.25	-2.1	-3.69	-1.03	-1.52
Cash per share	26.55	23.17	19.66	18.76	18.16
Book value per share	4.61	2.84	0.93	-1.96	1.3
Tangible book value per share	-31.77	-32.85	-34.78	-12.41	-30.25
Share holders equity per share	4.61	2.84	0.93	-1.96	1.3
Interest debt per share	1.19	9.05	9.06	9.19	17.14
Market cap	451.67M	504.29M	935.48M	886.39M	1.29B
Enterprise value	388.78M	493.62M	1.03B	981.07M	1.76B
P/E ratio	0.34	-2.87	-3.16	-1.85	6.66
Price to sales ratio	5.53	8.09	17.6	13.89	21.75
POCF ratio	-4.29	-7.08	-7.43	-26.32	-22.81
PFCF ratio	-4.07	-7.04	-7.42	-25.09	-22.53
P/B Ratio	2.87	5.2	29.54	-13.24	26.2
PTB ratio	2.87	5.2	29.54	-13.24	26.2
EV to sales	4.76	7.92	19.42	15.38	29.84
Enterprise value over EBITDA	1.68	-35.38	-25.24	-19.47	65.46
EV to operating cash flow	-3.69	-6.93	-8.19	-29.13	-31.28
EV to free cash flow	-3.5	-6.89	-8.19	-27.77	-30.9
Earnings yield	0.73	-0.09	-0.08	-0.13	0.04
Free cash flow yield	-0.25	-0.14	-0.13	-0.04	-0.04
Debt to equity	2.16	2.9	8.88	-3.69	12.97
Debt to assets	0.14	0.13	0.13	0.12	0.31
Net debt to EBITDA	-0.27	0.76	-2.37	-1.88	17.73
Current ratio	3.91	3.6	3.57	3.14	3.08
Interest coverage	0.14	-2.46	-1.78	-0.76	-9.4
Income quality	-0.32	1.6	1.7	0.28	-1.17
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.51	0.17	0.32	0.24	0.73
Research and developement to revenue	1.15	1.33	1.07	0.99	1.36
Intangibles to total assets	0.52	0.55	0.57	0.17	0.59
Capex to operating cash flow	0.05	0.01	0	0.05	0.01
Capex to revenue	-0.07	-0.01	0	-0.03	-0.01
Capex to depreciation	-2.2	-0.15	-0.03	-0.61	-0.34
Stock based compensation to revenue	0.04	0.03	0.2	0	-0.03
Graham number	31.62	9.06	6.72	12.42	6.14
ROIC	-0.05	-0.16	-0.2	-0.24	-0.12
Return on tangible assets	0.29	-0.04	-0.08	-0.07	0.06
Graham Net	-36.18	-37.02	-39.18	-42.37	-32.75
Working capital	810.69M	685.68M	621.17M	543.76M	549.71M
Tangible asset value	-1.09B	-1.12B	-1.19B	-424M	-1.14B
Net current asset value	-1.15B	-1.18B	-1.25B	-1.37B	-1.16B
Invested capital	2.16	2.9	8.88	-3.69	12.97
Average receivables	110.23M	95.21M	82.12M	72.27M	50.5M
Average payables	117.6M	93.9M	134.52M	118.39M	72.67M
Average inventory	26.69M	29.76M	53.5M	71.13M	66.3M
Days sales outstanding	123.82	112.73	145.9	82.32	64.98
Days payables outstanding	225.17	639.98	1.4K	697.12	175.54
Days of inventory on hand	141.55	151.29	838.24	420.39	383.79
Receivables turnover	0.73	0.8	0.62	1.09	1.39
Payables turnover	0.4	0.14	0.06	0.13	0.51
Inventory turnover	0.64	0.59	0.11	0.21	0.23
ROE	2.09	-0.45	-2.34	1.79	0.98
Capex per share	-0.17	-0.01	0	-0.05	-0.02

MOR.DE Frequently Asked Questions

What is MorphoSys AG stock symbol ?

MorphoSys AG is a DE stock and trading under the symbol MOR.DE

What is MorphoSys AG stock quote today ?

MorphoSys AG stock price is $67.7 today.

Is MorphoSys AG stock public?

Yes, MorphoSys AG is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 474.92K
Market Capitalization 2.56B
Employee 524
CEO Dr. Jean-Paul Kress M.D.
Headquarters Planegg,DE
IPO Date 1999-03-10
Website https://www.morphosys.com

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.